Physician-guided care in Florida and ColoradoFL (954) 953-3662  |  CO (720) 902-8247
Home / Guides / GLP-1 Medications for Adults 65 and Older: What Evidence Says

GLP-1 Medications for Adults 65 and Older: What Evidence Says

What the Wegovy and Zepbound labels say about adults 65 and older, with subgroup data on muscle loss, dehydration, kidney risk, falls and limits.

Before and after photo of a Healthy Weight Loss 4 U patient; individual results vary
Real Healthy Weight Loss 4 U patient photo. Individual results vary and are not guaranteed.

By the Healthy Weight Loss 4 U Clinical Content Team · Published October 20, 2026 · Updated October 20, 2026 · 9 min read

In short

The Zepbound label reports no overall differences in safety or effectiveness between adults 65 and older and younger adults in its weight studies, and the Wegovy label reports similar findings for some of its trials, but few people 75 and older were studied: 13 (0.5%) of Zepbound-treated and 23 (1%) of Wegovy-treated participants in the weight trials [1][2]. Older adults face particular questions about muscle loss, dehydration, kidney injury and falls, and the evidence on those questions is limited, mostly post hoc and largely sponsor-funded [3][4][8]. A licensed clinician decides after an evaluation.

Key takeaways

  • In the Zepbound label's pooled weight-reduction studies, 226 treated patients (9%) were 65 or older and 13 (0.5%) were 75 or older; the label reports no overall differences in safety or effectiveness by age [2].
  • In Wegovy's weight-reduction trials, 233 treated patients (9%) were 65 to under 75 and 23 (1%) were 75 or older; in the cardiovascular outcomes trial, patients 75 and older had more hip and pelvis fractures than placebo [1].
  • In the SURMOUNT-1 DXA substudy (160 people), about 25% of the weight lost on tirzepatide was lean mass; the summary reviewed did not report results for adults 65 and older [6].
  • Both labels warn of acute kidney injury due to volume depletion, mostly in people with nausea, vomiting or diarrhea leading to dehydration [1][2], and the NIH's MedlinePlus lists older adults as higher risk for dehydration [11].
  • Pooled data from six STEP trials in 358 adults 65 and older, presented as a conference abstract in 2026, reported a mean -15.4% weight change versus -5.1% with placebo and more serious adverse events with semaglutide (19.0% vs 12.7%) [4].

What do the Wegovy and Zepbound labels say about adults 65 and older?

Both FDA-approved labels report no overall differences in effectiveness between older and younger adults, with limits on what the trials could show. The current Zepbound label (revised 08/2026) states that in a pool of two fixed-dose weight-reduction studies, no overall differences in safety or effectiveness were observed between patients 65 and older and younger adults. It also says its sleep apnea studies did not include enough patients 65 or older to determine whether they respond differently [2].

The Wegovy label (revised 06/2026) is more segmented. For the weight-reduction trials it reports enrollment counts but gives no age conclusion. For the cardiovascular outcomes trial it states that no overall difference in effectiveness was observed between patients 65 and older and younger adults, and that patients 75 and older, on Wegovy and on placebo, reported more serious adverse reactions overall than younger adults. For the MASH trial it reports no overall differences in safety or effectiveness [1].

The indications themselves are not defined by age. Zepbound is indicated, with a reduced-calorie diet and increased physical activity, for adults with obesity or with overweight plus a weight-related condition, and for moderate to severe sleep apnea in adults with obesity [2]. Wegovy carries a similar adult weight-management indication, plus cardiovascular and MASH indications, and a pediatric indication from age 12 [1]. Age appears in the labels as information about who was studied, not as an eligibility cutoff.

On pharmacokinetics, the Wegovy label reports no clinically significant differences by age group (under 65, 65 to 74, and 75 or older), and the Zepbound label states that age (18 to 84 years) has no clinically relevant effect on tirzepatide levels [1][2]. Neither label sets age-based dosing changes in the sections reviewed. Labels are summaries of trials in which few of the oldest adults were enrolled, which the next section shows.

How many adults 65 and older were actually studied?

Adults 65 to 74 were represented in modest numbers and adults 75 and older were rare in the weight-reduction trials. In the Zepbound pool, 9% of treated patients were 65 or older and 0.5% were 75 or older [2]. In Wegovy's weight-reduction trials, 9% were 65 to under 75 and 1% were 75 or older [1]. Older adults were far better represented in Wegovy's cardiovascular outcomes trial, which enrolled adults 45 or older with established cardiovascular disease and a BMI of 27 or higher, excluding diabetes [1].

Older adults in the studies summarized in the labels (treated patients)
Label and trial65 to under 75 (or 65+)75 and older
Zepbound, pooled weight-reduction studies [2]226 (9%) aged 65+13 (0.5%)
Wegovy injection, weight-reduction trials [1]233 (9%)23 (1%)
Wegovy tablets, weight-reduction trial [1]16 (8%)5 (2%)
Wegovy injection, cardiovascular outcomes trial [1]2,656 (30%)703 (8%)
Wegovy injection, MASH trial (534 randomized) [1]138 (26%) aged 65+13 (2%)

The two pivotal weight trials also excluded people with diabetes: STEP 1 enrolled adults without diabetes, and SURMOUNT-1 excluded diabetes [5][12]. That leaves a gap for older adults who also have diabetes.

What do subgroup analyses show about weight loss and safety in older adults?

The available analyses suggest similar weight results in older adults, but they are small, post hoc and mostly sponsor-funded. A prespecified pooled analysis of the STEP-HFpEF trials (European Journal of Heart Failure, 2025) randomized 1,145 adults with obesity-related heart failure with preserved ejection fraction to semaglutide (573) or placebo (572) for 52 weeks. It grouped them by age: 101 under 55, 267 aged 55 to 64, 485 aged 65 to 74 and 292 (25.5%) aged 75 or older. Effects on symptoms and body weight were consistent across ages (interaction p = 0.80 for symptoms and 0.41 for body weight), and safety was described as consistent. Novo Nordisk funded it [3].

A pooled analysis of six STEP trials in adults 65 and older (358 people, 248 on semaglutide and 110 on placebo, out of 4,523 total) was presented in May 2026 at the European Congress on Obesity. It reported mean weight change of -15.4% versus -5.1% at 68 weeks, serious adverse events of 19.0% versus 12.7%, more constipation and dizziness with semaglutide, and similar fracture and hypoglycemia rates under 1% in both groups. About 90% were aged 65 to 74. We could only access a press release of this abstract, which is not peer reviewed, and Novo Nordisk researchers were among the authors [4].

A third analysis addressed a different question. Pooled SURPASS trials of tirzepatide for type 2 diabetes included 540 adults 65 or older with a BMI of 23 to under 30. They had larger rates than the overall trial population of adverse events leading to discontinuation (16.8% vs 8.5%) and serious adverse events (11.8% vs 8.1%). That analysis was post hoc, Lilly-funded, did not study adults 75 and older, and lacked frailty data. It concerns diabetes treatment, not the weight-management indication [7].

Does losing weight after 65 risk losing muscle?

Weight loss with GLP-1 medications includes some loss of lean mass, and the effect specifically in older adults is not well measured. Both labels state that the drugs lower body weight with greater fat mass loss than lean mass loss [1][2]. In the SURMOUNT-1 DXA substudy of 160 participants (124 on tirzepatide, 36 on placebo; 73% female), fat mass fell 33.9% and lean mass fell 10.9% on tirzepatide at week 72, versus 8.2% and 2.6% on placebo. About 25% of the weight lost was lean mass in both groups [6].

The concern is framed in the 2026 scoping review on this topic as follows: anti-obesity medications are increasingly used in older adults, who face risks of sarcopenia and sarcopenic obesity [8]. The trials behind the labels were not designed to answer that question, because they centered on body weight change [5][12], and the substudies that measured body composition were small.

A 140-person STEP 1 body-composition analysis, presented as a conference abstract, reported a 19.3% fall in fat mass and a 9.7% fall in lean mass with semaglutide, although lean mass rose as a share of body mass by about 3 percentage points [9]. Lean mass also fell in the placebo group (2.6%), so some lean mass change accompanies weight loss in general [6].

Percent change from baseline at week 72, SURMOUNT-1 DXA substudy (tirzepatide pooled doses, n = 124)

Source: [6] Look et al., Diabetes, Obesity and Metabolism 2025 (SURMOUNT-1 DXA substudy). Placebo: fat -8.2%, lean -2.6%, weight -5.3%.

A 2026 scoping review in Current Nutrition Reports on GLP-1 drugs in older adults concluded that muscle loss often accompanies weight loss and that evidence on muscle mass and physical performance is limited and inconsistent. Its authors suggest pairing treatment with resistance exercise, calorie control and adequate protein, plus dietitian involvement [8]. A 2025 joint advisory from four obesity and nutrition societies likewise lists muscle and bone loss as a challenge and names adequate protein and strength training as a priority, without age-specific targets in the summary reviewed [10].

Are dehydration and kidney problems a bigger concern for older adults?

Both labels warn about acute kidney injury caused by volume depletion, and older adults are a group at higher baseline risk of dehydration. The Wegovy and Zepbound labels report postmarketing cases of acute kidney injury, in some cases requiring hemodialysis, and say most occurred in people with nausea, vomiting or diarrhea leading to dehydration. Both advise monitoring kidney function in patients reporting reactions that could lead to volume depletion, especially around initiation and escalation (Zepbound label wording) [1][2]. The labels do not single out older adults for this warning in the sections reviewed.

MedlinePlus, from the NIH, states that older adults and people with certain diseases such as diabetes are at higher risk for dehydration, and lists vomiting and diarrhea among its causes [11]. Blood pressure is another overlap: in weight-reduction trials hypotension was reported in 1.3% of Wegovy-treated adults versus 0.4% with placebo and syncope in 0.8% versus 0.2% [1], and in 1.6% of Zepbound-treated patients versus 0.1% [2]. These are all-adult figures, not age-specific ones.

What about falls and fractures?

Falls are common in older adults, but the parts of the labels we reviewed do not contain a falls statement, so any link to these drugs is not established by label data. The CDC reports that over 14 million older adults, about 1 in 4, fall each year and that falls are the leading cause of injury for adults 65 and older [13]. The Zepbound label lists dizziness at 4% to 5% with Zepbound versus 2% with placebo in its adverse reaction table, without linking it to falls [2].

The Wegovy label does report a fracture signal in the oldest group. Its geriatric section states that patients 75 and older in the cardiovascular outcomes trial reported more hip and pelvis fractures on Wegovy than on placebo, and section 6.1 lists fractures in that age group at 2.4% (17 of 703) versus 0.6% (4 of 663) [1]. The pooled 65-plus analysis in the conference abstract found fracture rates under 1% in both groups [4]. The two sources involve different populations and ages, and neither is a dedicated falls study.

Hypoglycemia is a separate issue for people who also take diabetes drugs. The Zepbound label reports hypoglycemia in 4.2% versus 1.3% in a type 2 diabetes weight study, rising to 10.3% when taken with a sulfonylurea or insulin secretagogue, versus 2.1% without [2].

What are the evidence limits for older adults?

  • Very few adults 75 and older were studied in the weight-reduction trials: 0.5% to 1% of treated patients [1][2].
  • Key subgroup analyses are post hoc or conference abstracts, and manufacturers were involved: Novo Nordisk funded STEP-HFpEF and its researchers co-authored the STEP pooled abstract, and Lilly funded the SURPASS analysis [3][4][7].
  • The pivotal weight trials excluded diabetes, so results for older adults with diabetes come from other populations and drugs [5][12].
  • Body-composition data come from small substudies of 140 to 160 people that did not report age-specific results in the records reviewed [6][9].
  • No randomized trial reviewed here tested muscle strength, physical function, falls or fractures as primary outcomes in older adults on these drugs. The scoping review calls the muscle evidence limited and inconsistent [8].
  • Trials last 52 to 72 weeks, so long-term safety in older adults is not established by these studies [3][4][6].

What this means in practice

  • Age alone is not a label exclusion. The Zepbound label reports no overall differences in safety or effectiveness for adults 65 and older in its weight studies, with few of the oldest adults enrolled [2].
  • Ask for a full medication and health review, including diabetes drugs, because the Zepbound label links higher hypoglycemia rates to sulfonylureas and insulin secretagogues [2].
  • Tell your clinician promptly about vomiting, diarrhea, poor fluid intake or reduced urination, since the labels tie kidney injury to dehydration from gastrointestinal effects [1][2][11].
  • Discuss muscle protection early. Authors of a 2026 review suggest tailored resistance exercise, adequate protein and dietitian input, and a 2025 advisory names protein and strength training [8][10].
  • Report prior falls, dizziness or lightheadedness, given that falls affect about 1 in 4 older adults yearly and dizziness was more frequent than with placebo in the Zepbound table [2][13].
  • Ask how muscle and function will be monitored, since scale weight alone does not show lean mass change [6].
  • Treat the 2026 pooled STEP data for adults 65 and older as preliminary until a full peer-reviewed paper is available [4].

When to talk to a clinician

Whether a GLP-1 medication is appropriate at 65 or older depends on your health conditions, other medications, kidney function, muscle strength, fall history and goals, and only a licensed clinician can weigh those after an evaluation. The evidence summarized here describes groups of people, not you, and results are not guaranteed for anyone.

At Healthy Weight Loss 4 U, every program begins with a clinician evaluation, and that evaluation is the place to raise questions about age, muscle, hydration, kidney health and falls, and to ask how any treatment would be monitored. Bring a list of your medications and supplements to the visit.

Frequently asked questions

Are Wegovy and Zepbound approved for adults over 65?
The labels do not set an upper age limit in the sections reviewed. The Zepbound label reports no overall differences in safety or effectiveness between patients 65 and older and younger adults in its weight studies, and the Wegovy label reports counts of older participants by trial [1][2]. Whether a drug suits an individual is for a clinician to decide.
How many older adults were in the weight loss trials?
Few, especially those 75 and older. The Zepbound pool had 226 treated patients (9%) aged 65 or older and 13 (0.5%) aged 75 or older [2]. Wegovy's weight trials had 233 (9%) aged 65 to under 75 and 23 (1%) aged 75 or older [1]. The cardiovascular outcomes trial enrolled many more older adults [1].
Do GLP-1 drugs cause muscle loss in older adults?
They lower weight with greater fat than lean mass loss, per both labels [1][2]. In a tirzepatide DXA substudy of 160 people, about 25% of weight lost was lean mass [6]. Evidence specific to older adults on muscle mass and physical performance is described as limited and inconsistent [8].
Is dehydration a risk for older adults on these medications?
Both labels warn of acute kidney injury from volume depletion, mostly in people with nausea, vomiting or diarrhea leading to dehydration [1][2]. MedlinePlus lists older adults as at higher risk for dehydration [11]. Reporting vomiting, diarrhea or poor fluid intake to a clinician promptly is part of safe use.
Do these medications raise the risk of falls or fractures?
Falls are not addressed in the label sections we reviewed. The Wegovy label reports more hip and pelvis fractures in patients 75 and older than on placebo in its cardiovascular outcomes trial [1], while a conference abstract of adults 65 and older found fracture rates under 1% in both groups [4]. The evidence is inconsistent and limited.
Is there research on semaglutide specifically in people 65 and older?
Yes, but it is limited. A pooled analysis of six STEP trials (358 adults 65 and older) was presented as a 2026 conference abstract, and a peer-reviewed STEP-HFpEF analysis covered adults with heart failure across age groups, including 292 aged 75 or older [3][4]. The STEP-HFpEF analysis was funded by Novo Nordisk, and Novo Nordisk researchers co-authored the abstract.
Does the weight loss in older adults match younger adults?
The analyses reviewed suggest similar results. STEP-HFpEF found consistent body weight effects across age groups [3], and the 65-plus STEP pool reported a mean -15.4% versus -5.1% with placebo at 68 weeks [4]. These are subgroup analyses, so they cannot predict an individual's outcome.

Sources

  1. WEGOVY (semaglutide) prescribing information, revised 06/2026. Novo Nordisk (FDA-approved labeling), 2026. www.novo-pi.com/wegovy.pdf
  2. ZEPBOUND (tirzepatide) prescribing information, revised 08/2026. Eli Lilly and Company (FDA-approved labeling), 2026. pi.lilly.com/us/zepbound-uspi.pdf
  3. Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme. European Journal of Heart Failure, 2025. eprints.gla.ac.uk/373800
  4. Semaglutide analysis in adults 65 and older (Busetto, ECO 2026 abstract 1681), as released by the European Association for the Study of Obesity; conference abstract, not peer reviewed. European Association for the Study of Obesity via ScienceDaily, 2026. sciencedaily.com/releases/2026/05/260510234654.htm
  5. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. doi.org/10.1056/NEJMoa2032183
  6. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism, 2025. www.citedrive.com/en/discovery/body-composition-changes-during-weight-reduction-with-tirzepatide-in-the-scpsurmountscp1-study-of-adults-with-obesity-or-overweight/
  7. Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials. Diabetes Therapy, 2025. link.springer.com/article/10.1007/s13300-025-01711-0
  8. GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity. Current Nutrition Reports, 2026. avesis.ankara.edu.tr/yayin/6b890206-2eb2-4703-a05a-aa734ccdc50c/glp-1-receptor-agonists-for-obesity-management-in-older-adults-a-scoping-review-on-the-risk-of-sarcopenia-and-sarcopenic-obesity
  9. Semaglutide body composition exploratory analysis of the STEP 1 trial (conference abstract, ENDO 2021). Endocrine Society ENDO 2021 via Newswise, 2021. www.newswise.com/pdf_docs/16159288255831_Wilding%20Abstract.pdf
  10. Nutritional Priorities to Support GLP-1 Therapy for Obesity (joint advisory). American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, The Obesity Society, 2025. www.obesity.org/wp-content/uploads/2025/06/Joint_Nutritional-Priorities-to-Support-GLP-1-Therapy-for-Obesity.pdf
  11. Dehydration. MedlinePlus, National Library of Medicine, NIH, 2025. medlineplus.gov/ency/article/000982.htm
  12. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. doi.org/10.1056/NEJMoa2206038
  13. Older Adult Falls Data and Research. Centers for Disease Control and Prevention, undated, data through 2024. www.cdc.gov/falls/data-research/index.html
General information, not medical advice. Results vary and treatment depends on evaluation by a licensed clinician. This article was prepared by the Healthy Weight Loss 4 U Clinical Content Team from the published sources listed above. Nothing here is a recommendation for a specific person, and no treatment is started without an evaluation by a licensed clinician.

Keep reading

Protect Muscle During Weight Loss: What the Evidence Shows

Read →

Managing GLP-1 Side Effects: Nausea, Reflux, Red Flags

Read →

First 12 Weeks on a GLP-1: What to Expect, Per the Labels

Read →

Ozempic, Wegovy, Mounjaro, Zepbound: What Each Is FDA-Approved For

Read →

Questions about your own situation? A clinician can review your history and goals. Related: Personalized Weight Loss Counseling.

Book in Lighthouse Point, FL Book in Highlands Ranch, CO